Figure S1. TBX2 primers and anti-TBX2 antibody specificity and TBX2 transfection controls. TBX2 silencing by transfection with TBX2 siRNA (siTBX2) in MCF-7 confirmed using (A) western blotting and (B) reverse-transcription-quantitative PCR. (C) TBX2 protein expression in U-2 OS cells transfected for 48 h with the pT-REx-DEST30/TBX2-3XFlag (pTBX2). (D) TBX2 RNA expression in SiHa and Ca Ski cells treated with 0.25 µM of 5azadC and transfected with pT-REx-DEST30/TBX2-3XFlag (pTBX2) or the pT-REx-DEST30/empty (pCTRL). The data are presented as mean values from three independent experiments. Error bars represent the standard deviation. TBX2, T-box transcription factor 2; si, small interfering; 5azadC, 5-aza-2'-deoxycytidine.
Figure S2. 5azadC treatment downregulates E6 expression in the UPCI:SCC090 HPV-positive tongue cancer cells. (A) E6 mRNA relative expression in UPCI:SCC090 cells treated with 250 nM of 5azadC for 96 h. (B) E6, p53, p21 and actin protein expression in the UPCI:SCC090 cells treated with 250 nM of 5azadC during 96 h. 5azadC, 5-aza-2'-deoxycytidine.